Since concurrent durvalumab led to marginal increases in the measured Rb, including a statistically significant increase (p < 0.05) at the 5 Gy dose level compared to radiation alone, radioimmunotherapy with durvalumab may be part of the solution to local invasion and tumor recurrence. Here, RB1 is linked to neoplasm.